# US 2026/0042777 A1 · Piperidylurea compounds and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0042777 A1
- Document ID: US20260042777A1
- Status: Published application
- Kind: A1
- Application number: 19/290,944
- Filed: 2025-08-05
- Published: 2026-02-12
- Earliest claimed: 2024-08-07
- Assignees: Arcus Biosciences, Inc.
- Applicants: Arcus Biosciences, Inc.
- Inventors: Joshua R. Corbin; Sandeep Dhanju; Corinne Nicole Foley; Jeremy Fournier; Padmanabha V. Kattamuri; Manjunath Lamani; Manmohan Reddy Leleti; Pradeep Nareddy; Ehesan Ul Sharif; Joice Thomas; Monika Yadav
- Web page: https://patentgrep.com/patent/US20260042777A1

## CPC

- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 498/08: Bridged systems
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 451/14: containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/08: Bridged systems
- C07D 513/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are compounds having a structure according to Formula II, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

## Claims

### Claim 1

A compound having a structure of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
A is phenyl or 5- to 10-membered heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S;
X2 is CR7 or N; wherein R7, if present, is H, halogen, C1-C3 alkyl, or —NH2;
X3 is CR8 or N; wherein R8, if present, is H, halogen, C1-C3 alkyl, or —NH2;
X4 is CR9; and X5 is CR10; wherein R9 and R10 are independently H, halogen, C1-C3 alkyl, or —NH2;
m is 0, 1, 2, or 3;
R1 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, phenyl, 4- to 9-membered heterocycloalkyl, 5- to 10-membered heteroaryl, —O—R1a, or -Q-Rb; wherein the 4- to 9-membered heterocycloalkyl has 1-2 ring heteroatoms or heteroatom groups independently selected from N, O, S, and S(O)2; and the 5- to 10-membered heteroaryl has 1-4 ring heteroatoms independently selected from N, O, and S; the phenyl is unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, —CN, C1-C3 alkyl, and C1-C3 haloalkyl; and the 5- to 10-membered heteroaryl is unsubstituted or substituted with C1-C6 alkyl;
Q is C1-C6 alkylene, C1-C6 haloalkylene, or C3-C6 cycloalkylene;
R1a is C1-C6 alkyl, C3-C6 cycloalkyl, —(C1-C6 alkylene)-(C3-C6 cycloalkyl), —(C1-C6 alkylene)-(4- to 9-membered heterocycloalkyl), or phenyl; wherein the 4- to 9-membered heterocycloalkyl has 1-2 ring heteroatoms or heteroatom groups independently selected from N, O, S, and S(O)2; and wherein R1a is unsubstituted or substituted with 1-3 halogens; and
R1b is C1-C6 alkoxy, C3-C6 cycloalkyl, or phenyl; wherein R1b is unsubstituted or substituted with 1-3 halogens;
R2 is H or C1-C3 alkyl;
R3a, R3b, R3c, R3d are each independently H, halogen, or C1-C6 alkyl; and R4 is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, —(C1-C4 alkylene)-(C1-C3 alkoxy), or C1-C6 hydroxyalkyl; or
R3c and R4 together form a C1-C2 alkylene group;
Y is absent or C1-C6 alkylene;
R5a is C1-C6 alkyl, C3-C8 cycloalkyl, phenyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl; wherein the 5- to 10-membered heteroaryl has 1-4 ring heteroatoms independently selected from N, O, and S; the 4- to 10-membered heterocycloalkyl has 1-3 ring heteroatoms or ring heteroatom groups independently selected from N, O, S, and S(O)2; and R5a is unsubstituted or substituted with 1-4 R5d;
each R5d when present is independently selected from oxo, halogen, —OH, —NR5bR5c, C1-C6 alkyl, C1-C6 haloalkyl, C1-C3 haloalkoxy, C1-C6 alkoxy, C3-C8 cycloalkyl, C1-C4 hydroxyalkyl, —(C1-C4 alkylene)-(C1-C3 alkoxy), —(C1-C5 alkylene)-(C3-C8 cycloalkyl), —(C1-C6 alkylene)-(4- to 10-membered heterocycloalkyl), —(C1-C4 alkylene)-C(O)N(CH3)2, —S(O)2—(C1-C3 alkyl), —C(O)—(C1-C4 alkyl), —C(O)—(C1-C4 hydroxyalkyl), —C(O)O—(C1-C4 alkyl), —C(O)OH, —C(O)NH2, 4- to 10-membered heterocycloalkyl, and phenyl; and each of the 4- to 10-membered heterocycloalkyl independently has 1-3 ring heteroatoms or ring heteroatom groups independently selected from N, O, S, and S(O)2 and is independently unsubstituted or substituted with 1 or 2 substituents independently selected from OH, halo, and C1-C6 alkyl; and the C3-C8 cycloalkyl is unsubstituted or substituted with OH; or
two R5d are taken together with the atoms to which they are attached to form phenyl, 5- or 6-membered heteroaryl, or 4- to 6-membered heterocycloalkyl; wherein the 5- or 6-membered heteroaryl has 1-2 ring heteroatoms independently selected from N, O, and S; the 4- to 6-membered heterocycloalkyl has 1-3 ring heteroatoms or ring heteroatom groups independently selected from N, O, S, and S(O)2; and the 4- to 6-membered heterocycloalkyl is unsubstituted or substituted with C1-C6 alkyl; and
R5b and R5c are independently selected from H, C1-C3 alkyl, —C(O)—(C1-C4 alkyl), 4- to 9-membered heterocycloalkyl; wherein the 4- to 9-membered heterocycloalkyl has 1-3 ring heteroatoms or ring heteroatom groups independently selected from N, O, S, and S(O)2.

### Claim 2 (depends on 1)

The compound of claim 1 having a structure of Formula II-1:
wherein:
A is 5- to 10-membered heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S;
X2 is CH or N;
X3 is CH or N;
m is 0 or 1;
R1 is halogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl, —(C1-C6 alkylene)-C1-C6 alkoxy, —O—R1a, or -Q-R1b; wherein:
R1a is C1-C6 alkyl, C3-C6 cycloalkyl, or phenyl; and R1a is unsubstituted or substituted with 1-3 halogens;
Q is C1-C6 alkylene; and
R1b is phenyl; wherein R1b is unsubstituted or substituted with 1-3 halogens;
R2 is H or C1-C3 alkyl;
R3a, R3b, R3c, R3d are each independently H, halogen, or C1-C6 alkyl;
R4 is H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl;
Y is absent or C1-C6 alkylene;
R5a is C1-C6 alkyl, C3-C8 cycloalkyl, phenyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl; wherein the 5- to 10-membered heteroaryl has 1-4 ring heteroatoms independently selected from N, O, and S; the 4- to 10-membered heterocycloalkyl has 1-3 ring heteroatoms or ring heteroatom groups independently selected from N, O, S, and S(O)2; and R5a is unsubstituted or substituted with 1-4 R5d;
each R5d when present is independently selected from oxo, halo, —OH, —NR5bR5c, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, —(C1-C4 alkylene)-(C1-C3 alkoxy), —(C1-C5 alkylene)-(C3-C8 cycloalkyl), —S(O)2—(C1-C3 alkyl), —C(O)—(C1-C4 alkyl), —C(O)O—(C1-C4 alkyl), and phenyl; and
R5b and R5c are independently selected from H and C1-C3 alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X2 is N or CH and/or X3 is N.

### Claim at position 4

-5. (canceled)

### Claim 6 (depends on 1)

The compound of claim 1, wherein
(a) R2 is C1-C3 alkyl;
(b) R3c and R3d are H;
(c) R3a and R3b are independently H or F; and/or
(d) R4 is H.

### Claim at position 6

-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein A is pyrazinyl, pyridinyl, pyridazinyl, isoquinolinyl, 1,3,4-thiadiazolyl, or thiazolyl.

### Claim at position 8

-13. (canceled)

### Claim 14 (depends on 1)

The compound of claim 1, wherein A is
each of which is unsubstituted or substituted with 1 R1.

### Claim 15 (depends on 1)

The compound of claim 1, wherein m is 1.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R1 is halogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl, —(C1-C6 alkylene)-C1-C6 alkoxy, or —O—R1a.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R1 is —O—R1a.

### Claim at position 13

-20. (canceled)

### Claim 21 (depends on 1)

The compound of claim 1, wherein Y is absent.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The compound of claim 1, having a structure of Formula IIj or Formula IIj-1:
wherein for Formula IIj, X1 is CH or N.

### Claim 24 (depends on 23)

The compound of claim 23, wherein for Formula IIj, X1 is N and X2 is N.

### Claim 25

(canceled)

### Claim 26 (depends on 23)

The compound of claim 23, wherein R3a is H and R3b is F.

### Claim 27 (depends on 23)

The compound of claim 23, having a structure of Formula IIj-2, Formula IIj-3a, or Formula IIj-3b:

### Claim at position 21

-29. (canceled)

### Claim 30 (depends on 23)

The compound of claim 23, wherein R1a is ethyl.

### Claim 31 (depends on 1)

The compound of claim 1, having a structure of Formula IIo or Formula IIo-1:
wherein for Formula IIo, X0 is CH or N and m is 0 or 1.

### Claim 32 (depends on 31)

The compound of claim 31, wherein for Formula IIo, X0 is N and X2 is N.

### Claim 33

(canceled)

### Claim 34 (depends on 31)

The compound of claim 31, wherein R3a is H and R3b is F and/or R1 is halogen or C1-C6 alkyl.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The compound of claim 1, having a structure of Formula IIp:
wherein X00 is CH or N and m is 0 or 1.

### Claim 37 (depends on 36)

The compound of claim 36, wherein X00 is N and X2 is and/or R3a and R3b are each independently H or F.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The compound of claim 1, wherein R5a is C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 6-membered heteroaryl, or 5- to 9-membered heterocycloalkyl; wherein the 5- to 6-membered heteroaryl has 1 or 2 nitrogen ring heteroatoms; the 5- to 9-membered heterocycloalkyl has 1 or 2 ring heteroatoms independently selected from N and O; and R5a is unsubstituted or substituted with 1-3 R5d;
each R5d when present is independently selected from oxo, halo, —OH, —NR5bR5c, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, —(C1-C4 alkylene)-(C1-C3 alkoxy), —(C1-C5 alkylene)-(C3-C8 cycloalkyl), —S(O)2—(C1-C3 alkyl), and phenyl; and
R5b and R5c are independently selected from H and C1-C3 alkyl.

### Claim at position 32

-41. (canceled)

### Claim 42 (depends on 1)

The compound of claim 1, wherein R5a is 5- to 9-membered heterocycloalkyl; wherein the 5- to 9-membered heterocycloalkyl has 1 or 2 ring heteroatoms independently selected from N and O; and R5a is unsubstituted or substituted with 1-3 R5d;
each R5d when present is independently selected from oxo, halogen, —OH, —NR5bR5c, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, —(C1-C4 alkylene)-(C1-C3 alkoxy), —(C1-C5 alkylene)-(C3-C8 cycloalkyl), —S(O)2—(C1-C3 alkyl), and phenyl; and
R5b and R5c are independently selected from H and C1-C3 alkyl.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

The compound of claim 1, wherein R5a is methyl, ethyl, isopropyl,
and R5a is unsubstituted or substituted with 1-3 R5d;
each R5d when present is independently selected from oxo, halo, —OH, —NR5bR5c, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, —(C1-C4 alkylene)-(C1-C3 alkoxy), —(C1-C5 alkylene)-(C3-C8 cycloalkyl), —S(O)2—(C1-C3 alkyl), and phenyl; and
R5b and R5c are independently selected from H and C1-C3 alkyl.

### Claim 45 (depends on 1)

The compound of claim 1, wherein —Y—R5a is methyl, ethyl, isopropyl,

### Claim 46

A compound selected from the group consisting of:

### Claim 47

A compound selected from the group consisting of:

### Claim 48

A compound selected from the group consisting of:

### Claim 49 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 50 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim 51 (depends on 1)

A method of treating a disease, disorder, or condition, mediated at least in part by mast cell activation, said method comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim at position 43

-57. (canceled)
